RNA seq of human colon cancer cell line HT29 treated with nanocurcumin
This study explores the transcriptomic effects of Gemini-curcumin (Gemini-Cur), a nano formulated version of curcumin, on HT-29 colorectal cancer cells. RNA sequencing was performed on treated and control samples to identify differentially expressed RNAs. The dataset provides insights into the molecular mechanisms of Gemini-Cur and its potential in modulating gene expression. Overall design: Four total samples were analyzed, including two biological replicates of untreated HT-29 cells (Control) and two replicates of Gemini-Cur treated cells (Treatment). Cells were treated for 48 hours, after which total RNA was extracted for sequencing.